75 / 76
Confidence Through Clinical
and Real World Experience
1-3
Millions of Patients Treated
Across Multiple Indications
4
References:
1.
Patel M.R., Mahaffey K.W., Garg J.
et al.
Rivaroxaban versus warfarin in non-valvular atrial fibrillation.
N Engl J Med
. 2011;365(10):883–91.
2.
Tamayo S., Peacock W.F., Patel M.R.,
et al.
Characterizing major bleeding in patients with nonvalvular atrial fibrillation: A pharmacovigilance study of 27 467 patients taking rivaroxaban.
Clin Cardiol
. 2015;38(2):63–8.
3.
Camm A.J., Amarenco P., Haas S.
et al.
XANTUS: A Real-World, Prospective, Observational Study.
4.
Calculation based on IMS Health MIDAS, Database: Monthly Sales December 2015.
For full prescribing information, refer to the package insert approved by the Medicines Regulatory Authority (MCC). S4 XARELTO
®
10 (Film-coated tablets). Reg. No.: 42/8.2/1046. Each film-coated tablet contains rivaroxaban 10 mg.
PHARMACOLOGICAL
CLASSIFICATION:
A.8.2 Anticoagulants.
INDICATION:
Prevention of venous thromboembolism (VTE) in patients undergoing major orthopaedic surgery of the lower limbs. S4 XARELTO
®
15 and XARELTO
®
20 (Film-coated tablets). Reg. No.: XARELTO
®
15:
46/8.2/0111; XARELTO
®
20: 46/8.2/0112. Each film-coated tablet contains rivaroxaban 15 mg (XARELTO
®
15) or 20 mg (XARELTO
®
20).
PHARMACOLOGICAL CLASSIFICATION:
A.8.2 Anticoagulants.
INDICATIONS:
(1) Prevention of stroke and systemic
embolism in patients with non-valvular atrial fibrillation (SPAF); (2) Treatment of deep vein thrombosis (DVT) and for the prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE); (3) Treatment of pulmonary embolism (PE) and for the
prevention of recurrent pulmonary embolism (PE) and deep vein thrombosis (DVT).
HCR:
Bayer (Pty) Ltd, Reg. No.: 1968/011192/07, 27 Wrench Road, Isando, 1609. Tel: 011 921 5044 Fax: 011 921 5041.
L.ZA.MKT.GM.01.2016.1265
*Impact RX Data Oct - Dec 2015
NOAC:NonVitamin K OralAnticoagulant
#1 NOAC prescribed by Cardiologists
*